A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
Stopped The study was terminated early following assessment of the two co-primary endpoints showing the lack of efficacy of the study product.
Conditions
Interventions
- DRUG: GSK 2132231A
- DRUG: Placebo
Sponsor
GlaxoSmithKline